Ocular toxicity of intravitreal clarithromycin

Retina

Volumn 19, Issue 5, 1999, Pages 442-446

  Unal, Melih ^a   Peyman, Gholam A ^a   Liang, Chanping ^a   Hegazy, Hassan ^a   Molinari, Luiz C ^a   Chen, Junxin ^b   Brun, Scott ^b   Tarcha, Peter J ^b  

^a LSU EYE CENTER   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Clarithromycin; Clearance; Intravitreal injection; Retinal toxicity

Indexed keywords

CLARITHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG SAFETY; ELECTRORETINOGRAPHY; EYE TOXICITY; HISTOPATHOLOGY; NONHUMAN; RABBIT; RETINA;

EID: 0033499301     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-199919050-00015     Document Type: Article

References (25)

1. Barry AL, Thornsberry C, Jones RN. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. Antimicrob Agents Chemother 1987;31:343-345.
2. Fernandes PB, Bailer R, Swanson R, et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother 1986;30:865-873.
3. Hardy DJ, Hensey DM, Beyer JM, et al. Comparative in vitro activities of new 14-, 15-and 16-membered macrolides. Antimicrob Agents Chemother 1988;32:1710-1719.
4. Eliopoulos GM, Reiszner E, Ferraro MJ, Moellering RC. Comparative in vitro activity of A-56268 (TE-031), a new macrolide antibiotic. J Antimicrob Chemother 1987;20:671-675.
5. Fernandes PB, Baker WR, Freiberg LA, et al. New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. Antimicrob Agents Chemother 1989;33:78-81.
6. Fernandes PB, Hardy DJ. Comparative in vitro potencies of nine new macrolides. Drugs Exp Clin Res 1988;14:445-451.
7. Naik S, Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother 1989;33:1614-1616.
8. Fernandez-Martin J, Leport C, Morlat P, et al, Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother 1991;35:2049-2052.
9. Araujo FG, Prokocimer P, Lin T, Remington JS. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrob Agents Chemother 1992;36:2454-2457.
10. Chang HR, Rudareanu FC, Pechere JC. Activity of A-56268 (TE-031), a new macrolide, against Toxoplasma gondii in mice. J Antimicrob Chemother 1988;22:359-361.
11. Derouin F, Chastang C. Activity in vitro against Toxoplasma gondii in mice of azithromycin and clarithromycin alone and with pyrimethamine (letter). J Antimicrob Chemother 1990; 25:708-711.
12. Araujo FG, Prokocimer P, Remington JS. Clarithromycinminocycline is synergistic in a murine model of toxoplasmosis (letter). J Infect Dis 1992;165:788.
13. Helm CJ, Holland GN, Lin R, et al. Comparison of topical antibiotics for treating Mycobacterium fortuitum keratitis in an animal model. Am J Ophthalmol 1993;116:700-707.
14. Gross RH, Holland GN, Elias SJ, Tuz R. Corneal pharmacokinetics of topical clarithromycin. Invest Ophthalmol Vis Sci 1995;36:965-968.
15. Yatsunami J, Turuta N, Wakamatsu K, et al. Clarithromycin is a potent inhibitor of tumor-induced angiogenesis. Res Exp Med 1997;197:189-197.
16. Rodrigues AD, Roberts EM, Mulford DJ, et al. Oxidative metabolism of clarithromycin in the presence of human liver microsomes: major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997;25:623-630.
17. Tsang KW, Roberts P, Read RC, et al. The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration. J Antimicrob Chemother 1994;33:289-297.
18. Hardy DJ, Swanson RN, Rode RA, et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990; 34:1407-1413.
19. Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993;25:189-204.
20. Umeki S. Anti-inflammatory action of erythromycin: its inhibiting effect on neutrophil NADPH oxidase activity. Chest 1993;104:1191-1193.
21. Smith DK, Polverini PJ, Kunkel SL, et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994;179:1409-1415.
22. Oishi K, Sonoda F, Kobayashi S, et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994;62:4145-4152.
23. Hamada K, Kita E, Sawaki M, et al. Antitumor effect of erythromycin in mice. Chemotherapy 1995;41:59-69.
24. Kohno Y, Yoshida H, Suwa T, Suga T. Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. Antimicrob Agents Chemother 1989;33:751-756.
25. Whitman MS, Tunkel AR. Azithromycin and clarithromycin. Overview and comparison with erythromycin. Infect Control Hosp Epidemiol 1992;13:357-368.